The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 4 of 16
Back to Result List

The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients

Please always quote using this URN: urn:nbn:de:bvb:20-opus-148172
  • B cells have only recently begun to attract attention in the immunopathology of multiple sclerosis (MS). Suitable markers for the prediction of treatment success with immunomodulatory drugs are still missing. Here we evaluated the B cell response to brain antigens in n = 34 relapsing-remitting MS (RRMS) patients treated with glatiramer acetate (GA) using the enzyme-linked immunospot technique (ELISPOT). Our data demonstrate that patients can be subdivided into responders that show brain-specific B cell reactivity in the blood and patientsB cells have only recently begun to attract attention in the immunopathology of multiple sclerosis (MS). Suitable markers for the prediction of treatment success with immunomodulatory drugs are still missing. Here we evaluated the B cell response to brain antigens in n = 34 relapsing-remitting MS (RRMS) patients treated with glatiramer acetate (GA) using the enzyme-linked immunospot technique (ELISPOT). Our data demonstrate that patients can be subdivided into responders that show brain-specific B cell reactivity in the blood and patients without this reactivity. Only in patients that classified as B cell responders, there was a significant positive correlation between treatment duration and the time since last relapse in our study. This correlation was GA-specific because it was absent in a control group that consisted of interferon-\(\beta\) (IFN-\(\beta\))-treated RRMS patients (n = 23). These data suggest that GA has an effect on brain-reactive B cells in a subset of patients and that only this subset benefits from treatment. The detection of brain-reactive B cells is likely to be a suitable tool to identify drug responders.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Damiano M. Rovituso, Catharina E. Duffy, Michael Schroeter, Claudia C. Kaiser, Christoph Kleinschnitz, Antonios Bayas, Rebecca Elsner, Stefanie Kuerten
URN:urn:nbn:de:bvb:20-opus-148172
Document Type:Journal article
Faculties:Medizinische Fakultät / Institut für Anatomie und Zellbiologie
Medizinische Fakultät / Neurologische Klinik und Poliklinik
Language:English
Parent Title (English):Scientific Reports
Year of Completion:2015
Volume:5
Issue:14265
Source:Scientific Reports 5:14265 (2015). DOI: 10.1038/srep14265
DOI:https://doi.org/10.1038/srep14265
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:antibodies; cortical pathology; disability; disease; expression; lesions; multiple sclerosis; natural history; trial
Release Date:2018/11/08
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International